ArticleAnnals of medicine2025
Nonlinear association of a body shape index and hyperlipidemia: an American population-based cross-sectional study.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the association between A Body Shape Index (ABSI) and hyperlipidemia, and assess nonlinear relationships
methodsData from 21,013 adults in the National Health and Nutrition Examination Survey (NHANES, 2005-2020) were analyzed. Hyperlipidemia was defined using National Cholesterol Education Program (NCEP) criteria. ABSI was calculated as waist circumference/(BMI^(2/3) × H^(1/2)) and stratified into quartiles (Q1-Q4). Multivariable logistic regression models, adjusted for demographic characteristics, health behaviors, and clinical features, assessed the association between ABSI and hyperlipidemia. RCS and subgroup analyses explored nonlinearity and interactions, with sensitivity analyses excluding lipid-lowering medication users and participants who died within two years.
resultsHigher ABSI was significantly associated with increased hyperlipidemia risk across all models. In the fully adjusted model, each unit increase in ABSI corresponded to a 24% increased risk (OR = 1.24, 95% CI: 1.17-1.31). Quartile-based analysis revealed progressive risk increases, with the highest quartile demonstrating 68% higher odds compared to the lowest (OR = 1.68, 95% CI: 1.46-1.94 P for trend < 0.001). RCS analysis revealed a significant nonlinear inverse U-shaped relationship (P for nonlinearity < 0.001) with a threshold at 0.084. Participants with ABSI > 0.084 had 28% higher hyperlipidemia risk compared to those with ABSI ≤ 0.084 (OR = 1.28, 95% CI: 1.13-1.44). Subgroup analyses identified significant interactions with age (
conclusionThis study provides the first comprehensive evidence of a significant association between ABSI and hyperlipidemia. The identified threshold effect suggests that ABSI may serve as a valuable anthropometric tool for hyperlipidemia risk stratification. Future studies should validate causality and explore mechanisms underlying the observed nonlinear dynamics.This study provides the first comprehensive evidence of a significant ABSI-hyperlipidemia association. The threshold effect suggests ABSI may serve as a valuable anthropometric tool for hyperlipidemia risk stratification. Future studies should validate causality and explore mechanisms underlying the observed nonlinear dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.